LetterOne LetterOne LetterOne
L1 Health

Partnering with entrepreneurs to create platforms that transform healthcare

L1 Health is looking to develop industry leading platforms that transform healthcare. We partner with entrepreneurs and industry executives to identify and invest in creative ideas that take advantage of powerful, long-term global trends and have the potential to change healthcare and improve lives. We understand the time and operational focus required to achieve success. With over $3bn in evergreen capital, L1 Health can dedicate the time it takes to build industry leaders, invest throughout the economic cycle, and tailor its approach to each opportunity – from minority stakes to majority control, from start-up companies to industry leaders.

Stefan Linn

'The macro challenges of 2020 have validated our approach of investing in long-term trends and transformative platforms'

Stefan Linn

Our year in review

Looking back on a year of resilience, ingenuity and achievement.

Our year in review - L1 Health
$ 1.0 bn

Net assets under management (31 Dec 2021)

L1H AR

A year in review

L1 Health Annual Review 2022

We are pleased to publish L1 Health's Annual Review

L1 Health Annual Review 2022

The L1 Health team

Explore portfolio

In October 2019 L1 Health acquired Destination Pet and launched a new animal health and wellness platform in the US and Europe. Destination Pet is a leader in pet health care services and a trusted high-quality pet care and vet services provider.

Destination Pet

Formed in 2019, K2 HealthVentures (K2HV) is a start-up venture, providing life sciences companies at the venture and growth stages with innovative financing solutions.

K2 Health Ventures

In October 2021, L1 Health acquired Remedica Ltd. in a joint venture with Blantyre Capital. In 2023 L1 became sole owners of the business. Founded in 1980, Remedica is a leading pharmaceutical company and the largest exporter in Cyprus, specialized in the development, manufacturing and sale of both complex and essential branded generics.

In October 2021, L1 Health acquired Sun Wave Pharma in a joint venture with Blantyre Capital. In 2023 L1 became sole owners of the business. Sun Wave Pharma is a leading consumer health and nutraceutical company based in Romania.

Sun Wave Pharma

Our businesses